Thirty-one out of 83 patients (37%) with high-risk PC were the subject of our study. Information from (68)Ga-PSMA-PET imaging was used to individualize treatment plans to include suspicious lesions as well as possibly boost sites with tracer uptake in LN or the prostate bed. For evaluation, (68)Ga-PSMA-PET-positive LN were contoured in a patient dataset with a standard lymph drainage (RTOG consensus on CTV definition of pelvic lymph nodes) radiation field depicting color-coded nodes that would have been infield or outfield of that standard lymph drainage field and thereby visualizing typical patterns of failure of a "blind" radiation therapy after RPE and LAE.Compared to negative conventional imaging (CT/MRI), lesions suspicious for PC were detected in 27/31 cases (87.1%) by (68)Ga-PSMA-PET imaging, which resulted in changes to the radiation concept. There were 16/31 patients (51.6%) that received a simultaneous integrated boost (SIB) to a subarea of the prostate bed (in only three cases this dose escalation would have been planned without the additional knowledge of (68)Ga-PSMA-PET imaging) and 18/31 (58.1%) to uncommon (namely presacral, paravesical, pararectal, preacetabular and obturatoric) LN sites. Furthermore, 14 patients (45.2%) had a changed TNM staging result by means of (68)Ga-PSMA-PET imaging.
Compared to conventional CT or MRI staging, (68)Ga-PSMA-PET imaging detects more PC lesions and, thus, significantly influences radiation planning in recurrent prostate cancer patients enabling individually tailored treatment.European journal of nuclear medicine and molecular imaging. 2017 Jun 23 [Epub ahead of print]
Kilian Schiller, K Sauter, S Dewes, M Eiber, T Maurer, J Gschwend, S E Combs, G Habl
Go “Beyond the Abstract” - Read an article commentary written by the author
Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Strasse 22, 81675, Munich, Germany. ., Department of Radiation Oncology, Technical University of Munich (TUM), Ismaninger Strasse 22, 81675, Munich, Germany., Department of Nuclear Medicine, Technical University Munich (TUM), Munich, Germany., Department of Urology, Technical University Munich (TUM), Munich, Germany.